William Blair initiated coverage of Xencor (XNCR) with an Outperform rating. The firm believes the biopharmaceutical industry is entering a ...

Conference call with management will be held on April 16 at 2 pm hosted by JPMorgan. Webcast LinkStay Ahead of the Market: Discover ...

Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. PASADENA ...

This irresponsible form of political theater is on display regarding the necessary and critical role capital investing plays ...

Historically, BPDCN treatment relied on chemotherapy regimens adapted from leukemia or lymphoma protocols. However, recent breakthroughs have transformed the treatment paradigm. ELZONRIS (Stemline ...

The ionic liquid market is expected to be positively impacted by environmental regulations and the use of ionic liquids in ...

According to DelveInsight's analysis, the market for GIST is anticipated to increase during the forecast period (2025–2034), owing to the launch of e ...

Bassil Dahiyat, CEO of Xencor, told Endpoints: “We are one of many companies made up of a large percentage of immigrant staff, highly talented and trained. We cease to function without ...

PASADENA, Calif.—Bart Jan Cornelissen, the Senior Vice President and Chief Financial Officer of Xencor Inc . (NASDAQ:XNCR), recently sold 3,750 shares of the company's common stock. The transaction, ...

At close: April 17 at 4:00:01 PM EDT ...